TABLE 3.

Eep involvement in the production of iCF10, cCF10, and cAM373

Straina	Eep	Terminusb		Titerc
		N	C
JRC107(pJRC4)	+	iCF10	iCF10	32
JRC110(pJRC4)	-	iCF10	iCF10	<1
JRC107(pPCR4)	+	iCF10	cCF10	4,096
JRC110(pPCR4)	-	iCF10	cCF10	64
JRC107(pJRC2)	+	cAM373	cAM373	8,192
JRC110(pJRC2)	-	cAM373	cAM373	8,192
JRC107(pJRC3)	+	cAM373	cCF10	8,192
JRC110(pJRC3)	-	cAM373	cCF10	8,192

^aStrain JRC107 is cCF10 and GelE/SprE deficient but Eep positive (+); strain JRC110 is derived from JRC107 but is Eep deficient (−). See Materials and Methods for details.

^bThe N terminus of the peptide is native to either the iCF10 or the cAM373 propheromone sequence and is designated as such (see Fig. 2 and 3). The C terminus of the peptide is the active portion and is either cCF10, iCF10, or cAM373, as designated (see Fig. 2 and 3).

^cSupernatants (grown 6 h from a 10% overnight inoculum induced) were diluted twofold, and cCF10 or cAM373 activity is reported as the inverse of the largest dilution that was able to aggregate an OG1RF(pCF10) or OG1RF(pAM373) indicator strain. The iCF10 activity is reported as the extent of reduction of the ability to aggregate OG1RF(pCF10) relative to a parallel 50-ng/ml cCF10 control (see Materials and Methods). The 50-ng/ml control had a cCF10 titer of 512, and culture filtrates with iCF10 activity were diluted 1:50 in THB prior to determination of the iCF10 activity. The relative activities are representative of at least two independent experiments. A titer of <1 indicates that no active pheromone or inhibitor was observed at the dilutions examined.